Business Insider28d
Mersana Therapeutics: ‘Positive’ results from Phase 1 emiltatug ledadotin trial
Mersana Therapeutics (MRSN) announced positive initial clinical data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin, Mersana’s lead Dolasynthen ADC candidate ...
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on ...
Nasdaq28d
Mersana Therapeutics Reports Positive Phase 1 Results for Emiltatug Ledadotin in Triple-Negative Breast Cancer
Mersana Therapeutics has reported encouraging preliminary data from the Phase 1 trial of its lead antibody-drug conjugate, emiltatug ledadotin (Emi-Le), which targets B7-H4 in patients with ...
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $5.57 Consensus Target Price from Analysts
Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight analysts that are presently covering the company, Ratings reports ...
Yahoo Finance28d
Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?
On Friday, Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin. Emi-Le was generally well tolerated ...
Nasdaq28d
Mersana Therapeutics Receives Additional FDA Fast Track Designation for XMT-1660 in Advanced Breast Cancer Treatment
Mersana Therapeutics, Inc. announced that the FDA has granted an additional Fast Track designation for its drug XMT-1660, also known as emiltatug ledadotin (Emi-Le), aimed at treating advanced or ...
ETF Daily News25d
Mersana Therapeutics’ (MRSN) Outperform Rating Reiterated at Wedbush
Wedbush reiterated their outperform rating on shares of Mersana Therapeutics (NASDAQ:MRSN – Free Report) in a research report released on Friday morning,RTT News reports. They currently have a $ ...